8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
May 11, 2026·SEC
Material company update
Mar 24, 2026·SEC
Fractyl Health, Inc. Common Stock(GUTS)Earnings, Financials & Key Ratios
GUTS•NASDAQ
Price updated Jun 19, 2026
AboutFractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.Show more
- Revenue$0-100.0%
- EBITDA-$96M-3.1%
- Net Income-$141M-105.2%
- EPS (Diluted)-1.86-14.8%
- ROE-744.17%-207.9%
GUTS Key Insights
Fractyl Health, Inc. Common Stock (GUTS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 84 (top 16%)
✗Weaknesses
- ✗High debt to equity ratio of 6.5x
- ✗Profits declining 35.8% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 74.1% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when GUTS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GUTS Price & Volume
Fractyl Health, Inc. Common Stock (GUTS) stock price & volume — 10-year historical chart
Loading chart...
GUTS Growth Metrics
Fractyl Health, Inc. Common Stock (GUTS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-21.2%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM5.43%
Return on Capital
10 Years-170.55%
5 Years-91.05%
3 Years-102.95%
Last Year-101.18%
GUTS Recent Earnings
Fractyl Health, Inc. Common Stock (GUTS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (40%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.06+135.3%
$0.17
Rev
—
—
Q2 2026
Mar 24, 2026Metric
Actual
Est
EPS
$0.15+178.9%
$0.19
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.35-2.9%
$0.34
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.53-43.2%
$0.37
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.06vs $0.17+135.3% | — |
| Q2 2026 | Mar 24, 2026 | $0.15vs $0.19+178.9% | — |
| Q4 2025 | Nov 12, 2025 | $0.35vs $0.34-2.9% | — |
| Q3 2025 | Aug 12, 2025 | $0.53vs $0.37-43.2% | — |
Based on last 12 quarters of dataView full earnings history →
GUTS Peer Comparison
Fractyl Health, Inc. Common Stock (GUTS) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVAX | 1.5B | 9.13 | 3.59 | 64.69% | -14.73% | |||
 ELVN | 2.75B | 45.10 | -24.64 | -21.04% | 0.00 | |||
 RNAC | 282.94M | 9.63 | -1.92 | -92.81% | -85.51% | |||
 RMTI | 25.26M | 0.64 | -4.27 | -31.76% | -9.25% | -45.88% | 0.34 | |
 DNLI | 3.7B | 23.31 | -7.85 | -52.2% | 0.04 | |||
 VKTX | 3.52B | 30.38 | -9.52 | -71.31% | 0.00 | |||
 TERN | 4.77B | 52.95 | -51.41 | -20.02% | 0.00 | |||
 RDVT | 777.4M | 55.10 | 60.55 | 20.03% | 14.99% | 13.98% | 0.03 |
Compare GUTS vs Peers
Fractyl Health, Inc. Common Stock (GUTS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GUTS Income Statement
Fractyl Health, Inc. Common Stock (GUTS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 120K | 93K | 0 | 0 |
Revenue Growth % | - | - | - | - | - | -22.5% | -100% | -100% |
Cost of Goods Sold | 893K | 770K | 0 | 452K | 77K | 50K | 0 | 0 |
COGS % of Revenue | - | - | - | - | 64.17% | 53.76% | - | - |
Gross Profit | -893K▲ 0% | -770K▲ 13.8% | 0▲ 100.0% | -452K▲ 0% | 43K▲ 109.5% | 43K▲ 0.0% | 0▼ 100.0% | 0▲ 0% |
Gross Margin % | - | - | - | - | 35.83% | 46.24% | - | - |
Gross Profit Growth % | - | 13.77% | 100% | - | 109.51% | 0% | -100% | - |
Operating Expenses | 29.03M | 28.19M | 36.93M | 48.93M | 50.88M | 93.57M | 96.82M | 92.88M |
OpEx % of Revenue | - | - | - | - | 42399.17% | 100617.2% | - | - |
Selling, General & Admin | 8.14M | 5.76M | 10.49M | 14.58M | 0 | 0 | 22.28M | 17.25M |
SG&A % of Revenue | - | - | - | - | - | - | - | - |
Research & Development | 20.89M | 22.43M | 26.43M | 34.35M | 38.04M | 70.47M | 74.54M | 70.7M |
R&D % of Revenue | - | - | - | - | 31698.33% | 75775.27% | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 12.84M | 23.1M | 0 | 1000K |
Operating Income | -29.92M▲ 0% | -28.96M▲ 3.2% | -36.93M▼ 27.5% | -49.38M▼ 33.7% | -50.84M▼ 2.9% | -93.53M▼ 84.0% | -96.82M▼ 3.5% | -92.88M▲ 0% |
Operating Margin % | - | - | - | - | -42363.33% | -100570.97% | - | - |
Operating Income Growth % | - | 3.2% | -27.51% | -33.73% | -2.94% | -83.99% | -3.51% | - |
EBITDA | -29.03M | -28.19M | -36.25M | -48.93M | -50.55M | -92.85M | -95.69M | -91.76M |
EBITDA Margin % | - | - | - | - | -42125% | -99843.01% | - | - |
EBITDA Growth % | - | 2.88% | -28.59% | -34.98% | -3.3% | -83.69% | -3.05% | 4.25% |
D&A (Non-Cash Add-back) | 893K | 770K | 676K | 452K | 286K | 677K | 1.13M | 1.12M |
EBIT | -29.92M | -28.96M | -36.93M | -49.38M | -50.84M | -93.53M | -96.82M | -92.88M |
Net Interest Income | -635K | -1.5M | -1.44M | 797K | 1.26M | 4.15M | 1.54M | 1.63M |
Interest Income | 0 | 0 | 0 | 797K | 1.26M | 4.15M | 1.54M | 1.63M |
Interest Expense | 635K | 1.5M | 1.44M | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -673K | -1.52M | -1.81M | 2.93M | -26.25M | 24.84M | -44.14M | -15.12M |
Pretax Income | -30.59M▲ 0% | -30.48M▲ 0.4% | -38.73M▼ 27.1% | -46.45M▼ 19.9% | -77.09M▼ 66.0% | -68.69M▲ 10.9% | -140.95M▼ 105.2% | -108M▲ 0% |
Pretax Margin % | - | - | - | - | -64242.5% | -73864.52% | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -30.59M▲ 0% | -30.48M▲ 0.4% | -38.73M▼ 27.1% | -46.45M▼ 19.9% | -77.09M▼ 66.0% | -68.69M▲ 10.9% | -140.95M▼ 105.2% | -108M▲ 0% |
Net Margin % | - | - | - | - | -64242.5% | -73864.52% | - | - |
Net Income Growth % | - | 0.37% | -27.08% | -19.93% | -65.95% | 10.89% | -105.19% | -21.2% |
Net Income (Continuing) | -30.59M | -30.48M | -38.73M | -46.45M | -77.09M | -68.69M | -140.95M | -108M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.64▲ 0% | -0.86▼ 34.4% | -1.12▼ 30.2% | -1.34▼ 19.6% | -1.98▼ 47.8% | -1.62▲ 18.2% | -1.86▼ 14.8% | -1.42▲ 0% |
EPS Growth % | - | -34.38% | -30.23% | -19.64% | -47.76% | 18.18% | -14.81% | 5.43% |
EPS (Basic) | -0.64 | -0.86 | -1.12 | -1.34 | -1.98 | -1.62 | -1.86 | - |
Diluted Shares Outstanding | 47.61M | 47.61M | 47.61M | 47.61M | 47.61M | 43.54M | 75.82M | 75.82M |
Basic Shares Outstanding | 47.61M | 47.61M | 47.61M | 47.61M | 47.61M | 43.54M | 75.82M | 75.82M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
GUTS Balance Sheet
Fractyl Health, Inc. Common Stock (GUTS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 6.78M | 30.88M | 96.39M | 51.63M | 35.65M | 71.76M | 87.58M | 65.92M |
Cash & Short-Term Investments | 5.79M | 29.11M | 95.47M | 49.27M | 33.52M | 67.46M | 81.54M | 63.17M |
Cash Only | 5.79M | 29.11M | 95.47M | 49.27M | 33.52M | 67.46M | 81.54M | 63.17M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 22K | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | 66.92 | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 73K | 73K | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | 346.04 | 532.9 | - | - |
Other Current Assets | 0 | 0 | 915K | 2.36M | 2.03M | 4.23M | 6.04M | 2.75M |
Total Non-Current Assets | 2.16M | 3.88M | 6.16M | 9.33M | 40.56M | 36.31M | 33.83M | 33.47M |
Property, Plant & Equipment | 2.12M | 1.36M | 1.34M | 1.65M | 30.77M | 31.39M | 29.23M | 28.53M |
Fixed Asset Turnover | - | - | - | - | 0.00x | 0.00x | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 863K | 835K | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 4.25M | 4.25M | 4.25M | 4.25M | 4.25M |
Other Non-Current Assets | 32K | 2.52M | 4.82M | 2.56M | 4.7M | 666K | 337K | 4.94M |
Total Assets | 8.93M▲ 0% | 34.76M▲ 289.1% | 102.55M▲ 195.0% | 60.96M▼ 40.6% | 76.21M▲ 25.0% | 108.08M▲ 41.8% | 121.4M▲ 12.3% | 99.39M▲ 0% |
Asset Turnover | - | - | - | - | 0.00x | 0.00x | - | 0.00x |
Asset Growth % | - | 289.08% | 195.02% | -40.56% | 25.03% | 41.81% | 12.33% | -35.61% |
Total Current Liabilities | 3.41M | 10.92M | 23.65M | 7.31M | 11.19M | 19.77M | 18.33M | 15.41M |
Accounts Payable | 608K | 304K | 970K | 980K | 553K | 3.24M | 1.57M | 1.65M |
Days Payables Outstanding | 248.51 | 144.1 | - | 791.37 | 2.62K | 23.65K | - | - |
Short-Term Debt | 0 | 7.17M | 15.72M | 0 | 2.73M | 0 | 5.1M | 5.14M |
Deferred Revenue (Current) | 0 | 0 | -970K | -980K | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.94M | 672K | 5.13M | 3.3M | 4.4M | 7.39M | 6M | 8.62M |
Current Ratio | 1.99x | 2.83x | 4.07x | 7.06x | 3.19x | 3.63x | 4.78x | 4.28x |
Quick Ratio | 1.99x | 2.83x | 4.07x | 7.06x | 3.18x | 3.63x | 4.78x | 4.28x |
Cash Conversion Cycle | - | - | - | - | -2.21K | - | - | - |
Total Non-Current Liabilities | 149.52M | 8.89M | 288.22M | 305.96M | 390.09M | 59.88M | 93.61M | 62.6M |
Long-Term Debt | 14.9M | 8.12M | 287.33M | 305.09M | 342.48M | 30.16M | 30.59M | 55.68M |
Capital Lease Obligations | 0 | 0 | 334K | 465K | 28.51M | 27.38M | 25.96M | 79.01M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 134.62M | 769K | 555K | 409K | 19.1M | 2.33M | 37.07M | 6.92M |
Total Liabilities | 152.93M | 19.81M | 311.87M | 313.27M | 401.27M | 79.65M | 111.94M | 78.01M |
Total Debt | 14.9M | 15.29M | 304.34M | 306.81M | 373.72M | 62.5M | 61.65M | 60.82M |
Net Debt | 9.11M | -13.81M | 208.87M | 257.54M | 340.2M | -4.96M | -19.89M | -2.35M |
Debt / Equity | - | 1.02x | - | - | - | 2.20x | 6.52x | 2.84x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.66x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.03x |
Interest Coverage | -47.12x | -19.27x | -25.61x | - | - | - | - | - |
Total Equity | -144M▲ 0% | 14.95M▲ 110.4% | -209.32M▼ 1500.1% | -252.32M▼ 20.5% | -325.06M▼ 28.8% | 28.42M▲ 108.7% | 9.46M▼ 66.7% | 21.38M▲ 0% |
Equity Growth % | - | 110.38% | -1500.07% | -20.54% | -28.83% | 108.74% | -66.73% | -63.45% |
Book Value per Share | -3.02 | 0.31 | -4.40 | -5.30 | -6.83 | 0.65 | 0.12 | 0.28 |
Total Shareholders' Equity | -144M | 14.95M | -209.32M | -252.32M | -325.06M | 28.42M | 9.46M | 21.38M |
Common Stock | 20.75M | 0 | 0 | 0 | 0 | 0 | 1K | 1K |
Retained Earnings | -153.86M | -184.34M | -223.07M | -269.52M | -346.62M | -415.31M | -556.26M | -547.05M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -153.86M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GUTS Cash Flow Statement
Fractyl Health, Inc. Common Stock (GUTS) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -27.73M | -31.07M | -33.46M | -46.24M | -42.82M | -65.52M | -90.33M | -87.73M |
Operating CF Margin % | - | - | - | - | -35685.83% | -70452.69% | - | - |
Operating CF Growth % | - | -12.06% | -7.69% | -38.2% | 7.4% | -53% | -37.86% | -53.94% |
Net Income | -30.59M | -30.48M | -38.73M | -46.45M | -77.09M | -68.69M | -140.95M | -108M |
Depreciation & Amortization | 893K | 770K | 676K | 452K | 286K | 677K | 1.13M | 1.12M |
Stock-Based Compensation | 2.52M | 1.63M | 2.09M | 3.14M | 4.3M | 14.43M | 6.68M | 5.28M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 274K | 517K | 795K | -2.14M | 28.7M | -21.52M | 43.21M | 16.86M |
Working Capital Changes | -824K | -3.51M | 1.71M | -1.24M | 989K | 9.59M | -395K | -2.99M |
Change in Receivables | 0 | 0 | 0 | 0 | -22K | 22K | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | -73K | 0 | 73K | 0 |
Change in Payables | 0 | -304K | 666K | 0 | -427K | 2.69M | -1.67M | 170K |
Cash from Investing | -97K | -2K | -51K | -56K | -359K | -1.76M | -557K | -109K |
Capital Expenditures | -97K | -2K | -51K | -56K | -359K | -1.76M | -557K | -109K |
CapEx % of Revenue | - | - | - | - | 299.17% | 1897.85% | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 15.16M | 54.39M | 99.88M | 4.35M | 27.44M | 101.23M | 104.96M | 108.89M |
Debt Issued (Net) | 14.95M | -7K | -7K | 4.03M | 28.35M | -187K | -457K | -471K |
Equity Issued (Net) | 0 | 54.37M | 99.85M | 321K | 0 | 103.69M | 105.42M | 109.37M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 217K | 24K | 40K | 0 | -911K | -2.28M | 0 | 0 |
Net Change in Cash | -12.66M▲ 0% | 23.32M▲ 284.1% | 66.37M▲ 184.6% | -46.2M▼ 169.6% | -15.74M▲ 65.9% | 33.94M▲ 315.6% | 14.08M▼ 58.5% | 21.06M▲ 0% |
Free Cash Flow | -27.83M▲ 0% | -31.07M▼ 11.7% | -33.51M▼ 7.8% | -46.3M▼ 38.2% | -43.18M▲ 6.7% | -67.29M▼ 55.8% | -90.89M▼ 35.1% | -87.83M▲ 0% |
FCF Margin % | - | - | - | - | -35985% | -72350.54% | - | - |
FCF Growth % | - | -11.67% | -7.85% | -38.15% | 6.73% | -55.82% | -35.07% | -9.73% |
FCF per Share | -0.58 | -0.65 | -0.70 | -0.97 | -0.91 | -1.55 | -1.20 | -1.16 |
FCF Conversion (FCF/Net Income) | 0.91x | 1.02x | 0.86x | 1.00x | 0.56x | 0.95x | 0.64x | 0.81x |
Interest Paid | 0 | 1.04M | 1.03M | 0 | 762K | 3.13M | 0 | 1.04M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GUTS Key Ratios
Fractyl Health, Inc. Common Stock (GUTS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -203.87% | - | - | - | -241.68% | -744.17% | -4573.89% |
Return on Invested Capital (ROIC) | - | -8181.98% | -1557.23% | -374.68% | -363.51% | -1115.05% | -2498.04% |
Gross Margin | - | - | - | 35.83% | 46.24% | - | - |
Net Margin | - | - | - | -64242.5% | -73864.52% | - | - |
Debt / Equity | 1.02x | - | - | - | 2.20x | 6.52x | 2.84x |
Interest Coverage | -19.27x | -25.61x | - | - | - | - | - |
FCF Conversion | 1.02x | 0.86x | 1.00x | 0.56x | 0.95x | 0.64x | 0.81x |
Revenue Growth | - | - | - | - | -22.5% | -100% | -100% |
Related:GUTS Dividend History·GUTS Revenue History·GUTS Price History·GUTS P/E History·GUTS Financial Ratios·GUTS Institutional Holders
GUTS SEC Filings & Documents
Fractyl Health, Inc. Common Stock (GUTS) SEC filings — annual & quarterly reports (10-K, 10-Q)
GUTS Frequently Asked Questions
Fractyl Health, Inc. Common Stock (GUTS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Fractyl Health, Inc. Common Stock (GUTS) saw revenue decline by 100.0% over the past year.
Fractyl Health, Inc. Common Stock (GUTS) reported a net loss of $108.0M for fiscal year 2025.
Dividend & Returns
Fractyl Health, Inc. Common Stock (GUTS) has a return on equity (ROE) of -744.2%. Negative ROE indicates the company is unprofitable.
Fractyl Health, Inc. Common Stock (GUTS) had negative free cash flow of $87.8M in fiscal year 2025, likely due to heavy capital investments.